GGTLC1 and metabolic dysfunction-associated steatohepatitis: NASH was associated with the presence of insulin resistance (OR 4.76 [1.23–18.52], p = 0.045) and metabolic syndrome (OR 3.41 [1.15–11.22], p = 0.038), as well as higher levels of gamma-glutamyl transpeptidase (γ-GT) (Table 1).